Race Oncology Ltd. (AU:RAC) has released an update.
Race Oncology Ltd is set to present at the TechKnow Invest Roadshow in Sydney and Melbourne at the end of July 2024, highlighting investment opportunities and discussing their lead chemotherapeutic asset, bisantrene, particularly in relation to cancer survivorship and cardioprotection. The company invites shareholders and potential investors to register for free and meet the executive team. Race is actively seeking partnerships and exploring bisantrene’s potential in various oncology indications and as part of its mission to advance cancer care.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.
